Vistagen Therapeutics (NASDAQ:VTGN) and Targeted Medical Pharma (OTCMKTS:TRGM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.
This is a breakdown of current recommendations and price targets for Vistagen Therapeutics and Targeted Medical Pharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Targeted Medical Pharma||0||0||0||0||N/A|
Vistagen Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 481.40%. Given Vistagen Therapeutics’ higher possible upside, equities research analysts plainly believe Vistagen Therapeutics is more favorable than Targeted Medical Pharma.
Institutional & Insider Ownership
8.6% of Vistagen Therapeutics shares are owned by institutional investors. 13.4% of Vistagen Therapeutics shares are owned by company insiders. Comparatively, 69.2% of Targeted Medical Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Vistagen Therapeutics has a beta of -0.14, suggesting that its share price is 114% less volatile than the S&P 500. Comparatively, Targeted Medical Pharma has a beta of -0.52, suggesting that its share price is 152% less volatile than the S&P 500.
This table compares Vistagen Therapeutics and Targeted Medical Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Targeted Medical Pharma||N/A||N/A||N/A|
Valuation and Earnings
This table compares Vistagen Therapeutics and Targeted Medical Pharma’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vistagen Therapeutics||$1.25 million||42.73||-$14.34 million||($1.11)||-1.55|
|Targeted Medical Pharma||N/A||N/A||N/A||N/A||N/A|
Targeted Medical Pharma has lower revenue, but higher earnings than Vistagen Therapeutics.
Vistagen Therapeutics beats Targeted Medical Pharma on 5 of the 8 factors compared between the two stocks.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of drug rescue NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.
Targeted Medical Pharma Company Profile
Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers' compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California.
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.